DEXCOM INC DXCM
Surgical & Medical Instruments & Apparatus · Nasdaq
Выручка
$3.62B
+24.5% Год к году
Чистая прибыль
$541.50M
+58.7% Год к году
Общие активы
$6.48B
+3.5% Год к году
EPS
1.30
+58.5% Год к году
Advertisement
Отчет о доходах
| Период | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 FY |
|---|---|---|---|---|---|---|---|---|
| Revenues | $3.40B | $2.19B | $1.04B | $3.62B | $2.92B | $1.93B | $921.00M | $2.91B |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | $2.01B | $1.28B | $589.00M | $2.29B | $1.78B | $1.19B | $561.90M | $1.88B |
| R&D Expense | $450.90M | $293.40M | $145.20M | $505.80M | $412.90M | $277.50M | $141.50M | $484.20M |
| SG&A Expense | $969.50M | $638.10M | $310.10M | $1.19B | $958.40M | $652.00M | $319.30M | $1.01B |
| Operating Income (Loss) | $588.80M | $346.30M | $133.70M | $597.70M | $411.10M | $259.10M | $101.10M | $391.20M |
| Interest Expense | — | — | — | — | — | — | — | — |
| Net Income (Loss) | $569.00M | $285.20M | $105.40M | $541.50M | $424.50M | $289.90M | $146.40M | $341.20M |
| EPS (Diluted) | 1.42 | 0.71 | 0.27 | 1.30 | 1.04 | 0.71 | 0.36 | 0.82 |
Балансовый отчет
| Период | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 FY |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $6.34B | $6.34B | $6.34B | $6.48B | $6.48B | $6.48B | $6.48B | $6.26B |
| Current Assets | $4.03B | $4.03B | $4.03B | $4.30B | $4.30B | $4.30B | $4.30B | $4.43B |
| Cash & Equivalents | $1.84B | $1.16B | $904.90M | $566.30M | $621.20M | $939.20M | $851.20M | $642.30M |
| Accounts Receivable | $1.22B | $1.22B | $1.22B | $1.01B | $1.01B | $1.01B | $1.01B | $973.90M |
| Inventory | $629.10M | $629.10M | $629.10M | $542.60M | $542.60M | $542.60M | $542.60M | $559.60M |
| PP&E (Net) | — | — | — | — | — | — | — | — |
| Goodwill | $24.20M | $24.20M | $24.20M | $22.80M | $22.80M | $22.80M | $22.80M | $25.20M |
| Total Liabilities | $3.59B | $3.59B | $3.59B | $4.38B | $4.38B | $4.38B | $4.38B | $4.20B |
| Current Liabilities | $2.14B | $2.14B | $2.14B | $2.93B | $2.93B | $2.93B | $2.93B | $1.56B |
| Long-Term Debt | — | — | — | — | — | — | — | — |
| Stockholders Equity | $2.10B | $2.10B | $2.10B | $2.13B | $2.07B | $2.07B | $2.07B | $2.04B |
Отчет о движении денежных средств
| Период | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 FY |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.15B | $486.80M | $183.80M | $748.50M | $688.10M | $488.60M | $209.20M | $669.50M |
| Investing Cash Flow | $229.40M | $36.60M | $100.20M | $-507.20M | $96.20M | $-114.10M | $74.80M | $-521.50M |
| Financing Cash Flow | $-164.20M | $10.80M | $12.50M | $-318.60M | $-733.20M | $3.30M | $4.70M | $-552.50M |
| Stock Repurchases | $187.20M | $0 | — | $688.70M | $750.00M | — | — | $557.70M |
Похожие компании
BAXTER INTERNATIONAL INC
BAX
BECTON DICKINSON & CO
BDX
BOSTON SCIENTIFIC CORP
BSX
3M CO
MMM
INSULET CORP
PODD
RESMED INC
RMD
Solventum Corp
SOLV
STRYKER CORP
SYK
Узнайте больше
How to Find Any SEC Filing in Two MinutesCash-Flow Quality: Profit Is an Opinion, Cash Is a FactValuation Basics: P/E, P/S and What They Actually Tell YouDividends: How Companies Pay Shareholders and How to Read ThemHow to Read a 10-K Annual Report (Without Falling Asleep)Understanding Earnings Per Share (EPS)How to Read a Cash Flow StatementHow to Read a Balance SheetHow to Read an Income Statement
Данные получены из публичной базы данных U.S. SEC EDGAR. Этот сайт не предоставляет инвестиционные советы.